Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00588068 · ClinicalTrials.gov registry record
Molecular Characterization of Neuroblastic Tumor: Correlation With Clinical Outcome
A clinical trial of Neuroblastoma, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- 2,070
- Enrollment target
- 1
- Study location
NCT00588068: Recruiting study of Neuroblastoma, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00588068 is a study of Neuroblastoma that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 2,070 participants, above the 217-participant average among 94 other Neuroblastoma trials with a reported enrollment target (854% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00588068, a study of Neuroblastoma, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- 2,070 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to find out the genetic and biochemical makeup of your neuroblastic tumor, which influences its aggressiveness and the suitable therapy. These research studies include surface marker analysis, cytogenetics, cancer genes,genome sequencing, tumor growth-related genes and tumor growth in test tubes. Your blood, marrow, and hematopoietic stem cell samples will also be tested for tumors or leukemia cells, and your serum tested for anti-tumor antibodies.
Primary Outcome
Before surgery a maximum of 5 blood drawings (20-30 ml) will be performed per year (at least one month apart) per patient
Conditions Studied
Interventions
- OTHER Tumor and Marrow Markers
Study Locations (1)
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,070 participants |
| Start Date | 2000-09-26 |
| Est. Completion | 2026-09 |
What NCT00588068 shows while recruiting
NCT00588068 is an observational study that tracks outcomes without assigning an intervention. Its 2,070 participants enrollment target places it among the larger protocols in the corpus, above the 217-participant average among 94 other Neuroblastoma trials with a reported enrollment target (854% higher).
The record links to 1 condition, with Neuroblastoma appearing as the primary indexed condition, and to 1 intervention - of which Tumor and Marrow Markers is the first listed.
NCT00588068 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT00588068 about?
NCT00588068 is a clinical study titled "Molecular Characterization of Neuroblastic Tumor: Correlation With Clinical Outcome". The purpose of this study is to find out the genetic and biochemical makeup of your neuroblastic tumor, which influences its aggressiveness and the suitable therapy. These research studies include surface marker analysis, cytogenetics, cancer genes,genome sequencing, tumor growth-related genes and t...
What is the current status of trial NCT00588068?
This trial is currently recruiting. The enrollment target is 2,070 participants. The study started on 2000-09-26. Estimated completion is 2026-09.
What conditions does trial NCT00588068 study?
This clinical trial studies the following conditions: Neuroblastoma.
What interventions are being tested in trial NCT00588068?
The interventions under investigation include: Tumor and Marrow Markers (OTHER).
Who is sponsoring clinical trial NCT00588068?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00588068 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuroblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00588068's enrollment target sits among peer trials
2,070 3rd of 94 higher than 92 of 94 other Neuroblastoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neuroblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
MCT for the Harvard/UCSF ROBIN Center
RECRUITING · NA
-
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
RECRUITING · Phase 1
-
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
RECRUITING · Phase 1
-
Neuroblastoma Biology Study
RECRUITING
-
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow
RECRUITING · Phase 2
-
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06666192 · 2,067 participants · NA
The Ohio State University (OSU) SCREEN Community Program
- NCT04373564 · 2,076 participants · Phase 4
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
- NCT07168993 · 2,063 participants · NA
Evaluate the Clinical Performance of the Flow Cytometry - FlowPath Lung Test as a Sensitive and Specific Non-invasive Diagnostic of Sputum Samples to Identify/Detect the Presence of Lung Cancer in High-risk Individuals Who Have Existing Lung Nodules, 6 to <30 mm in Diameter, Determined by LDCT.
- NCT04871542 · 2,062 participants
Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI